Aligos Therapeutics (ALGS) director granted 5,860 stock options at $5.50 strike

Rhea-AI Filing Summary

Aligos Therapeutics director Margarita Chavez received a grant of stock options covering 5,860 shares of common stock. The options have an exercise price of $5.50 per share and expire on June 25, 2036.

According to the grant terms, all 5,860 options will vest and become exercisable as to 100% of the underlying shares on the earlier of the first anniversary of the June 25, 2026 grant date or immediately prior to Aligos Therapeutics' 2027 annual stockholder meeting, provided she continues to serve the company through that vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chavez Margarita

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,860	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 5,860 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 5,860 options Exercise price: $5.50 per share Expiration date: June 25, 2036 +1 more

4 metrics

Option grant size 5,860 options Stock Option (Right to Buy) awarded June 25, 2026

Exercise price $5.50 per share Strike price for each option on Aligos common stock

Expiration date June 25, 2036 Option term end for 5,860 granted options

Post-transaction derivative holdings 5,860 options Total options held directly after grant

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 5.5000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-25T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:38 PM Accepted by SEC EDGAR 06/29/2026 - 04:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chavez Margarita

(Last) (First) (Middle)

C/O ALIGOS THERAPEUTICS, INC.

1 CORPORATE DRIVE, 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aligos Therapeutics, Inc. [ ALGS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.5	06/25/2026		A		5,860		(1)	06/25/2036	Common Stock	5,860	$0	5,860	D

Explanation of Responses:

1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.

	/s/ Lesley Ann Calhoun, as attorney-in fact for Margarita Chavez	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Aligos Therapeutics (ALGS) director Margarita Chavez report on this Form 4?

Margarita Chavez reported receiving a grant of stock options for 5,860 shares of Aligos Therapeutics common stock. These are compensation-related derivative securities, not an open-market purchase or sale of existing shares.

What are the key terms of Margarita Chavez’s Aligos (ALGS) stock option grant?

The grant covers 5,860 options at a $5.50 exercise price per share, expiring on June 25, 2036. Each option represents the right to buy one share of Aligos common stock at that exercise price after vesting.

How and when do Margarita Chavez’s Aligos (ALGS) options vest?

All 5,860 options vest 100% on a single date, which is the earlier of the first anniversary of the June 25, 2026 grant or immediately before Aligos’ 2027 annual stockholder meeting, subject to her continuous service with the company.

Did Margarita Chavez buy or sell Aligos Therapeutics (ALGS) shares in the market?

No market trade occurred in this filing. The Form 4 shows a compensation-related option grant coded as “A” (award or other acquisition), not an open-market buy or sell of Aligos common stock.

How many Aligos (ALGS) derivative securities does Margarita Chavez hold after this transaction?

Following the transaction, Chavez holds 5,860 stock options related to Aligos common stock according to the filing. These options are held directly and become exercisable only after the specified vesting date is reached.